Vai al contenuto principale
xMedica

NCT07685808ClinicalTrials.gov

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing…

Fase 2360 partecipanti ricercati22 centri1 paese

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-07-06; recorded start 2026-07-28
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 360 participants (target), run at 22 sites.

How this score is built
  • Enrolment25/40

    360 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration6/10

    Planned over about 18 months

  • Sponsor scale9/10

    Regeneron Pharmaceuticals has led 250 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

Patologie

  • Overweight or Obesity

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Key Inclusion Criteria: 1. Body Mass Index (BMI) ≥30.0 kg/m\^2 to \<45.0 kg/m\^2 at screening OR 2. BMI ≥27.0 kg/m\^2 at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary Artery Disease (CAD), Heart failure, established cerebrovascular disease as described in the protocol Key Exclusion Criteria: 1. Previous or current diagnosis of Type 1 or Type 2 diabetes at screening 2. Change in body weight \>5 kg within approximately 3 months before screening as described in the protocol 3. Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions as described in the protocol 4. History of acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones 5. History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 2
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento360 partecipanti ricercati

Sponsor e collaboratori

  • Regeneron Pharmaceuticals Sponsor

Bracci e interventi

  • Olatorepatide arm 1EXPERIMENTAL
  • Olatorepatide arm 2EXPERIMENTAL
  • Olatorepatide arm 3EXPERIMENTAL
  • Olatorepatide arm 4EXPERIMENTAL
  • Olatorepatide arm 5EXPERIMENTAL
  • Matching Placebo arm 6ACTIVE_COMPARATOR

Interventi

  • Farmaco Olatorepatide

    Administered per the protocol

  • Farmaco Placebo

    Administered per the protocol

Esiti misurati

  1. Esito primario

    Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Orizzonte temporale Up to approximately 60 weeks

  2. Esito primario

    Severity of TEAEs

    Orizzonte temporale Up to approximately 60 weeks

  3. Esito primario

    Percent change in body weight

    Orizzonte temporale From baseline to week 52

  4. Esito secondario

    Olatorepatide concentrations

    Orizzonte temporale Up to approximately 60 weeks

  5. Esito secondario

    Occurrence of Anti-Drug Antibody (ADA) to olatorepatide

    Orizzonte temporale Up to approximately 52 weeks

  6. Esito secondario

    Magnitude of ADA to olatorepatide

    Orizzonte temporale Up to approximately 52 weeks

Date

Date
Data di inizio28 luglio 2026 (effettiva)
Conclusione primaria21 gennaio 2028 (stimata)
Conclusione21 gennaio 2028 (stimata)
Prima pubblicazione6 luglio 2026 (effettiva)
Ultimo aggiornamento18 novembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltanovembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

22 centri stanno reclutando

United States

United States
StrutturaCittàStato o regioneStato
Flourish Research, Ravenswood RheumatologyChicagoIllinoisIn reclutamento
Charter Research LLC - ChicagoChicagoIllinoisIn reclutamento
Alliance for Multispecialty Research (AMR) Clinical MiamiDoralFloridaIn reclutamento
AMR Clinical - Fort MyersFort MyersFloridaIn reclutamento
Tribe Clinical ResearchGreenvilleSouth CarolinaIn reclutamento
AGA Clinical TrialsHialeahFloridaIn reclutamento
Flourish Research, Nature Coast Clinical ResearchInvernessFloridaIn reclutamento
Flourish Research, Jacksonville Center for Clinical ResearchJacksonvilleFloridaIn reclutamento
AMR Clinical - LexingtonLexingtonKentuckyIn reclutamento
K2 Medical Research Maitland LLC, Main OfficeMaitlandFloridaIn reclutamento
AMR Clinical - MobileMobileAlabamaIn reclutamento
NYC Research IncNew YorkNew YorkIn reclutamento
AMR Clinical - Chicago Oak BrookOak BrookIllinoisIn reclutamento
Velocity Clinical Research - OmahaOmahaNebraskaIn reclutamento
Rochester Clinical ResearchRochesterNew YorkIn reclutamento
Flourish Research, Legacy Oaks TowerSan AntonioTexasIn reclutamento
The IMA Group, IMA Clinical Research St. PetersburgSt. PetersburgFloridaIn reclutamento
Charter Research LLC - The VillagesThe VillagesFloridaIn reclutamento
Diablo Clinical Research - Flourish ResearchWalnut CreekCaliforniaIn reclutamento
Chase Medical ResearchWaterburyConnecticutIn reclutamento
AMR Clinical WichitaWichitaKansasIn reclutamento
Clinical Site Partners, LLC DBA Flourish ResearchWinter ParkFloridaIn reclutamento

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 18 novembre 2026

    Centro aggiunto

    1 site added (22 total)

    2122

  2. 13 ottobre 2026

    Centro aggiunto

    3 sites added (21 total)

    1821

  3. 29 settembre 2026

    Centro aggiunto

    13 sites added (18 total)

    518

  4. 20 agosto 2026

    Stato modificato

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  5. 20 agosto 2026

    Reclutamento aperto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  6. 20 agosto 2026

    Centro aggiunto

    5 sites added (5 total)

    05